Bionyra Pharma launches with $165M Series A to chase next-gen immunology drugs

What's the deal? Bionyra Pharma launched with $165 million to develop drugs targeting inflammatory disorders. The Paris-based startup is led by Frédéric Marrache, a SanofiDealroom has a profile for this one. Try Dealroom → veteran who most recently served as the company's global project head for clinical development in immunology and inflammation.

The Series A round was co-led by Jeito CapitalDealroom has a profile for this one. Try Dealroom → and Sofinnova Partners. Marrache and Sofinnova co-founded Bionyra in 2025.

Why now? The next generation of immunology drugs is chasing new targets, with candidates in the hands of big pharma firms including Merck, Roche, and partners Sanofi and Teva Pharmaceuticals.

Bionyra in-licensed three assets — two from China-based TrueLab Biopharmaceutical and one from New Jersey's NovaRock BiotherapeuticsDealroom has a profile for this one. Try Dealroom →. Its most advanced program, BYN-002, is a monoclonal antibody that blocks tumour necrosis factor-like ligand A (TL1A), a signalling protein that drives inflammation. TL1A's role in gastrointestinal inflammation has made it a hot target.

What could go wrong? Bionyra enters a crowded field. It is competing against late-clinical assets from far larger rivals, leaving little room for delay. The company must also prove its in-licensed candidates offer a real advantage over rival programs already further along.

The signal: The launch reflects how immunology, supercharged by blockbusters like Sanofi's Dupixent, is drawing fresh capital and talent toward next-generation targets. To pick its assets, Bionyra used Sofinnova's proprietary technology, which maps the innovation landscape weekly and surfaced more than 100 opportunities to review. That data-driven, in-licensing approach signals a leaner path to building a pipeline — buying promising science rather than discovering it from scratch.

Read more: MedCity News